SAD/MAD Study to Assess Safety, Tolerability, PK & PD of MEDI1814 in Subjects With Mild-Moderate Alzheimer's Disease.

Completed · Phase 1 · Has a placebo group

Conditions studied: Mild-Moderate Alzheimer's Disease, Healthy Elderly

In brief

The purpose of this study is to assess the safety, drug levels and effects on the body of 1 or 3 injections of MEDI1814, in people with mild to moderate Alzhiemer's Disease or healthy elderly people.

Key facts

Study ID

NCT02036645

Run by

AstraZeneca

People needed

77

Starts

2014-02-04

Expected to finish

2016-09-15

Last updated by the study team

2019-06-03

Who can join

Age: 55 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Research Site — Glendale, California, United States
• Research Site — Long Beach, California, United States
• Research Site — Panorama City, California, United States
• Research Site — Hallandale, Florida, United States
• Research Site — Hialeah, Florida, United States
• Research Site — Miami, Florida, United States
• Research Site — Orlando, Florida, United States
• Research Site — Baltimore, Maryland, United States
• Research Site — Oklahoma City, Oklahoma, United States
• Research Site — Salt Lake City, Utah, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.